Histopathological Characteristics

Oct 13, 2025 by orovajewels.com 104 views

Introduction

Basal cell carcinoma is a type of malignant neoplasm originating from non-neatinized cells that appear from the basal layer of epidermis. In recent years, the incidence of basal cell carcinoma has continued to increase, making it a serious attention in the field of dermatology health. This carcinoma has a variety of clinical and histopathological characteristics that can vary between individuals. One important aspect that is often observed is the expression of P53, which usually shows over-expression in cases of basal cell carcinoma.

Background

Basal cell carcinoma is the most common type of skin cancer, accounting for approximately 80% of all skin cancer cases. It is a slow-growing cancer that typically affects older adults, with a peak incidence between the ages of 50 and 70. The exact cause of basal cell carcinoma is still unknown, but it is believed to be related to a combination of genetic and environmental factors, including exposure to ultraviolet (UV) radiation from the sun or tanning beds.

Objectives

The purpose of this study is to identify clinical and histopathological characteristics and see the expression of immunohistochemical P53 in patients with basal cell carcinoma. This study aims to provide a better understanding of the characteristics of basal cell carcinoma, which can help in the diagnosis and treatment of this disease.

Methodology

This study used an observational descriptive study with a latitude cut design, which observes ten patients diagnosed with basal cell carcinoma based on history and clinical examination. The study was conducted at H Adam Malik Hospital Medan, and the data was collected from patient records and histopathological examination reports.

Results

From the results of the study, most basal cell carcinoma patients are male (70%), with an age range of 61-70 years (50%). The most common basal cell carcinoma lesions are ulcers (70%), followed by nodules (30%). This lesion appears most often in the face area, especially on the cheeks (40%), then on the forehead, nose, and temples (each 20%). On average, patients experience this disease for 3-5 years. In addition, research found that there was no family history relevant to 60% of patients.

Histopathological Characteristics

Histopathological characteristics found also show the dominance of nodular types (40%), with superficial types (20%), keratotic type (20%), pigment type, and basoskuamosa type (10%). The nodular type is characterized by a well-defined border and a central ulceration, while the superficial type is characterized by a flat or slightly raised lesion with a thin layer of epidermis.

Immunohistochemical Expression P53

On immunohistochemical examination, positive P53 expression 3 in 60% of patients, followed positive 2 (20%) and positive 1 (20%). P53 is a tumor suppressor protein that plays a crucial role in regulating cell growth and division. Over-expression of P53 has been observed in various types of cancer, including basal cell carcinoma.

Conclusion

The conclusion of this study shows that the most basal cell carcinoma occurs in men over the age of 60 years, with a clinical picture in the form of an ulcer in the cheek area. The nodular type dominates in histopathological characteristics, while immunohistochemical results show positive P53 expressions, which can be an important indicator in understanding the mechanism of basal cell pathology.

Implications

The importance of this study lies in a better understanding of the characteristics of basal cell carcinoma, so that it can help in the diagnosis and treatment that is more effective for patients. In addition, further research can be carried out to explore the more targeted therapy development potential by considering biomarker expressions such as P53.

Limitations

This study has several limitations, including the small sample size and the lack of control group. Further studies with larger sample sizes and control groups are needed to confirm the findings of this study.

Future Directions

Future studies can explore the relationship between P53 expression and the clinical and histopathological characteristics of basal cell carcinoma. Additionally, further research can be carried out to explore the potential of P53 as a biomarker for basal cell carcinoma.

Conclusion

In conclusion, this study provides a better understanding of the clinical and histopathological characteristics of basal cell carcinoma, as well as the expression of immunohistochemical P53 in patients with this disease. The findings of this study can help in the diagnosis and treatment of basal cell carcinoma, and can also provide a basis for further research into the potential of P53 as a biomarker for this disease.

Frequently Asked Questions

Q: What is basal cell carcinoma?

A: Basal cell carcinoma is a type of malignant neoplasm originating from non-neatinized cells that appear from the basal layer of epidermis. It is the most common type of skin cancer, accounting for approximately 80% of all skin cancer cases.

Q: What are the clinical characteristics of basal cell carcinoma?

A: The clinical characteristics of basal cell carcinoma include a slow-growing tumor that typically affects older adults, with a peak incidence between the ages of 50 and 70. The most common lesions are ulcers (70%), followed by nodules (30%). This lesion appears most often in the face area, especially on the cheeks (40%), then on the forehead, nose, and temples (each 20%).

Q: What are the histopathological characteristics of basal cell carcinoma?

A: The histopathological characteristics of basal cell carcinoma include the dominance of nodular types (40%), with superficial types (20%), keratotic type (20%), pigment type, and basoskuamosa type (10%). The nodular type is characterized by a well-defined border and a central ulceration, while the superficial type is characterized by a flat or slightly raised lesion with a thin layer of epidermis.

Q: What is the role of P53 in basal cell carcinoma?

A: P53 is a tumor suppressor protein that plays a crucial role in regulating cell growth and division. Over-expression of P53 has been observed in various types of cancer, including basal cell carcinoma. In this study, positive P53 expression was observed in 60% of patients, followed by positive 2 (20%) and positive 1 (20%).

Q: What are the implications of this study?

A: The importance of this study lies in a better understanding of the characteristics of basal cell carcinoma, so that it can help in the diagnosis and treatment that is more effective for patients. In addition, further research can be carried out to explore the more targeted therapy development potential by considering biomarker expressions such as P53.

Q: What are the limitations of this study?

A: This study has several limitations, including the small sample size and the lack of control group. Further studies with larger sample sizes and control groups are needed to confirm the findings of this study.

Q: What are the future directions of this research?

A: Future studies can explore the relationship between P53 expression and the clinical and histopathological characteristics of basal cell carcinoma. Additionally, further research can be carried out to explore the potential of P53 as a biomarker for basal cell carcinoma.

Q: What can patients do to prevent basal cell carcinoma?

A: Patients can take several steps to prevent basal cell carcinoma, including:

Avoiding exposure to ultraviolet (UV) radiation from the sun or tanning beds
Wearing protective clothing and applying sunscreen with a Sun Protection Factor (SPF) of 30 or higher
Avoiding smoking and secondhand smoke
Eating a healthy diet rich in fruits and vegetables
Getting regular skin checks and screenings

Q: What are the treatment options for basal cell carcinoma?

A: The treatment options for basal cell carcinoma include:

Surgical excision
Mohs surgery
Radiation therapy
Topical treatments, such as imiquimod or 5-fluorouracil
Systemic treatments, such as vismodegib or sonidegib

Q: What is the prognosis for patients with basal cell carcinoma?

A: The prognosis for patients with basal cell carcinoma is generally good, with a high cure rate. However, the prognosis can vary depending on the stage and location of the tumor, as well as the patient's overall health.